UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Ocera Therapeutics, Inc.
(Name of Subject Company)
Ocera Therapeutics, Inc.
(Names of Persons Filing Statement)
COMMON STOCK, PAR VALUE $0.00001 PER SHARE
(Title of Class of Securities)
67552A108
(CUSIP Number of Class of Securities)
Ocera Therapeutics, Inc.
Linda Grais
Chief Executive Officer
555 Twin Dolphin Drive, Suite 615
Redwood City, California 94065
(650) 475-0150
(Name, Address and Telephone Number, including area code, of Agent For Service)
With copies to:
Mitchell S. Bloom, Esq.
Daniel Lang, Esq.
Andrew H. Goodman, Esq.
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, New York 10018
(212) 813-8800
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 5.03, 7.01 and 9.01 of the Current Report on Form 8-K filed by Ocera Therapeutics, Inc. on November 2, 2017 (including all exhibits attached thereto) is incorporated herein by reference.
